Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study

BACKGROUND: Inadequately controlled symptoms incur a substantial burden on patients with neuroendocrine tumors and carcinoid syndrome (CS). The effectiveness of telotristat ethyl (TE) with a somatostatin analog for uncontrolled CS diarrhea has been demonstrated in clinical trials and observational s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulke, Matthew H, Kennecke, Hagen F, Murali, Kris, Joish, Vijay N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485853/
https://www.ncbi.nlm.nih.gov/pubmed/34611437
http://dx.doi.org/10.2147/CMAR.S330429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485853/
https://www.ncbi.nlm.nih.gov/pubmed/34611437
http://dx.doi.org/10.2147/CMAR.S330429

Ejemplares similares